Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

PCSK9 inhibitors

- PMLiVE

Sanofi cuts $925m deal for MannKind’s inhaled insulin

French company bolsters diabetes business with Afrezza collaboration

Sanofi reception

Sanofi asks Emcure to sell its cancer drugs in India

Will hand over marketing of Taxotere, Jevtana, Fludara and Fasturtec

Sanofi reception

Sanofi and Regeneron pay $67.5m to speed alirocumab review

Buy FDA priority review voucher from BioMarin

- PMLiVE

Amgen closes on second-line use for Kyprolis

Multiple myeloma therapy posts positive interim phase III results

- PMLiVE

Amgen cuts workforce and facilities despite profit leap

US biopharma plans 12-15 per cent workforce reduction

- PMLiVE

Amgen launches bowel cancer web portal in Spain

Aims to help healthcare professionals understand about personalised medicine

- PMLiVE

Amgen’s Sensipar follow-up clears phase III trial

AMG 416 meets objectives in hyperparathyroidism

dengue fever mosquito

Sanofi’s dengue vaccine could debut in 2015

End in sight after 20-year wait for first effective vaccine

- PMLiVE

FDA to review Sanofi’s Lantus successor

Decision on company’s next generation insulin Toujeo expected early next year

- PMLiVE

Amgen and Boehringer drugs win FDA breakthrough status

Leukaemia drug and Pradaxa antidote will benefit from accelerated regulatory processes

Kite Pharma once again looks to Amgen

William Go and Jeff Aycock fourth and fifth senior figures to join from Amgen this year

- PMLiVE

ADA: Novo says switching to Tresiba could reduce NHS costs

Real world data backs insulin’s ability to reduce hypoglycaemia in people with diabetes

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links